Odyssey Therapeutics, Inc. Financials
ODTX
All currency values in $ millions unless otherwise noted
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | -$1 | $3 | $4 | $1 |
| Operating Income | -$166 | -$161 | -$135 | -$133 |
| Non-Operating | ||||
| Net Interest Expense | -$0 | -$0 | -$0 | -$0 |
| Income Tax Expense | -$1 | -$1 | $0 | $0 |
| Net Income | ||||
| Net Income | -$165 | -$149 | -$129 | -$126 |
| Per Share Data | ||||
| Revenue Per Share | -$0.02 | – | – | – |
| EPS (Basic) | -$5.46 | – | – | – |
| EPS (Diluted) | -$5.46 | – | – | – |
| Shares Outstanding | 30.3M | – | – | – |
Odyssey Therapeutics (ODTX) financials: revenue, profit and margins
Odyssey Therapeutics (ODTX) generated about -$697,000.00 in revenue and -$165 million in net income (a 23,720.2% net margin) over the trailing twelve months, growing at roughly 69.4% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Odyssey Therapeutics's (ODTX) revenue?+
Odyssey Therapeutics generated about -$697,000.00 in revenue over the trailing twelve months. Revenue has grown at roughly 69.4% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Odyssey Therapeutics profitable?+
Odyssey Therapeutics reported about -$165 million in net loss over the trailing twelve months, a net margin of roughly 23,720.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Odyssey Therapeutics's profit margins?+
Odyssey Therapeutics runs an operating margin of about 23,764.0%, a net margin of about 23,720.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Odyssey Therapeutics growing?+
Odyssey Therapeutics's revenue has compounded at roughly 69.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ODTX's margins and free cash flow. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with ODTX
Held by ETFs
ODTX is in 3 US ETFs. The largest of them, with ODTX's weight in each:
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ODTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.